Skip to main content

Table 3 Percentage increase in antibody titers 28 days post vaccination

From: Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

  All patients
(n = 226)
(missinga: 24/28)
bDMARDs monotherapy
(n = 80)
(missinga: 8/14)
bDMARDs + DMARDs
(n = 110)
(missinga: 13/11)
Rituximab
(n = 5)
(missinga: 1/0)
Systemic disorders
(n = 18)
(missinga: 1/1)
Other
(n = 13)
(missinga: 1/2)
Controls
(n = 15)
(missinga: 4/2)
A/Cal H1N1pdm09 62.7 (31.9–100.6) 44.9 (9.2–92.4) 82.2 (43.4–131.4) 2.2 (-45.6–129.2) 30.8 (-83.9–104.0) 108.2 (23.6–250.6) 74.2 (4.9–189.3)
A/Swi H3N2 74.9 (48.3–106.3) 89.9 (51.8–137.6) 64.3 (36.1–98.5) 63.3 (-86.9–206.9) 96.2 (38.5–177.9) 77.1 (17.7–166.5) 193.2 (96.8–336.5)
B/Phu Yamagata 12.3 (-98.3–28.4) 5.1 (-87.9–25.7) 6.7 (-91.8–23.9) 71.8 (5.1–180.9) 20.2 (-91.5–57.9) 37.2 (-99.6–88.9) 53.9 (12.5–110.5)
  1. Abbreviations: DMARDs disease modifying antirheumatic drugs; bDMARD biological DMARDs
  2. Data are % (95 % CI). a Numbers missing pre-vaccine and post-vaccine, respectively
  3. A linear mixed model was used to estimate the increases from pre-vaccine to post-vaccine adjusted for the number of days between vaccination and post vaccination blood sampling. Percentage increase is reported at day 28 post vaccination
\